Bioanalytical Method Development And Validation For Simultaneous Estimation Of Clopidogrel And Pantoprazole | 18760
ISSN: 2155-9872

Journal of Analytical & Bioanalytical Techniques
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Bioanalytical method development and validation for simultaneous estimation of clopidogrel and pantoprazole

5th International Conference and Exhibition on Analytical & Bioanalytical Techniques

Jinesh B Nagavi and B M Gurupadayya

Accepted Abstracts: J Anal Bioanal Tech

DOI: 10.4172/2155-9872.S1.019

A simple, sensitive, rapid, robust and reproducible method for the bioanalytical determination of clopidogrel and pantoprazole in human plasma was developed using reverse phase high performance liquid chromatographic method. The analysis was performed on Shimadzu UFLC, C 8 (250?4.6 mm, 5 μm) column with a mobile phase consisting of 0.03 M potassium dihydrogen ortho phosphate buffer (pH 3), acetonitrile in the ratio of 40:60 (v/v) with a flow rate of 1.2 mL/min. The analyte was monitored with UV detector at 240 nm. In the developed method pantoprazole elutes at retention time of 1.9 min and clopidogrel at 5.5 min. The proposed method is having linearity in the concentration range 10-50 μg/ml for both clopidogrel and pantoprazole. The method was validated with respect to system suitability, linearity, precision, least limit of detection (LLOD) and least limit of quantification (LLOQ), accuracy (recovery), ruggedness, robustness, stability, forced degradation studies (specificity). The proposed method can be readily utilized for bulk drug and pharmaceutical formulations in human plasma (patients) administered with clopidogrel and pantoprazole.